Chronic Kidney Disease and Acute Kidney Injury in the COVID-19 Era: In the Search for New Biomarkers to Improve Decision Making

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 October 2021) | Viewed by 747

Special Issue Editors

1. Kidney Resuscitation and Acute Purification Therapies, Sanidad de Castilla y León and University of Valladolid, Zamora and Valladolid, Spain
2. Transplantation Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Interests: pharmacoepidemiology; pharmacometrics; pharmaceutical regulatory sciences; biopharmaceuticals; nanopharmaceuticals
Special Issues, Collections and Topics in MDPI journals
Pharmacological Big Data Laboratory, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain
Interests: psychoneuropharmacology; psychopharmacology; pharmacoepidemiology; toxicology; substance abuse
Special Issues, Collections and Topics in MDPI journals
1. Service of Nephrology, Valais Hospital, Sion, Switzerland
2. Organ Transplant Center, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
3. Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
Interests: kidney injury
Department of Nephrology, Hôpital du Valais, 1950 Sion, Switzerland
Interests: chronic kidney disease; nutrition; exercice; meabolism

Special Issue Information

Dear Colleagues,

Coronavirus disease 2019 (COVID-19) has contributed to a change in the concept of healthcare, involving several diseases and patients affected by these diseases. Current needs demand more personalized support for patients through more focused decision making by clinicians. Indeed, well-known susceptible patient populations such as those affected by chronic kidney disease (CKD) may be especially vulnerable to more severe COVID-19, present acute deterioration of kidney function, and undergo more intensive treatments compared to individuals without previous CKD. Furthermore, individuals with previous normal kidney function may be affected by acute kidney injury (AKI) during COVID-19 and will subsequently have persistent deteriorated kidney function, which may then evolve into CKD. Prognostic biomarkers are thus necessary. Most importantly, the search of suitable markers can go beyond metabolites, inflammation products, and omics products. The use of certain medicines, including dialyzers, and other procedures (interventions) can be linked with a worse prognosis in patients, and thus, such procedures can be implemented to identify high-risk individuals. In this context, considering that observational evidence is remarkably interesting and has an unprecedented impact, this type of evidence is especially welcomed. With the objective of a more individualized decision-making process concerning individuals with CKD and AKI in this new era marked by the pandemic, which is rapidly evolving with the advent of vaccines, this Special Issue entitled “Chronic Kidney Disease and Acute Kidney Injury in the COVID-19 Era: In the Search for New Biomarkers to Improve Decision Making” aims to compile original research articles and review articles on all potential candidates to prognostic biomarkers for these patients.

Prof. Dr. Francisco Herrera-Gómez
Prof. Dr. F. Javier Álvarez
Dr. Gabriella Guzzo
Prof. Dr. Daniel Teta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic kidney disease
  • acute kidney injury
  • COVID-19
  • biomarkers
  • prognosis

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop